98%
921
2 minutes
20
Purpose: We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials And Methods: We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results: Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion: The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582469 | PMC |
http://dx.doi.org/10.4143/crt.2021.1083 | DOI Listing |
Neurorehabil Neural Repair
September 2025
Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, UK.
Background: Gait impairment in Parkinson's disease (PD) occurs early and pharmaceutical interventions do not fully restore this function. Visual cueing has been shown to improve gait and alleviate freezing of gait (FOG) in PD. Technological development of digital laser shoe visual cues now allows for visual cues to be used continuously when walking.
View Article and Find Full Text PDFPhotochem Photobiol
September 2025
Universidade Estadual Do Oeste Do Paraná (UNIOESTE), Cascavel, Brazil.
The study investigated the impact of different treatments on recovery from calcaneal tendinopathy in rats, focusing on the gastrocnemius muscle. Tendinopathy is caused by repetitive overload, leading to structural collagen damage and chronic muscle inflammation. Three therapeutic approaches were compared: photobiomodulation (PBM), advanced platelet-rich fibrin (A-PRF) injection, and a combination of the two.
View Article and Find Full Text PDFAllergy
September 2025
Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
Hypersensitivity reactions to quinolones (QHRs) have been increasing in frequency, thus classifying them as the second most frequently implicated class of antibiotics in hypersensitivity reactions (HRs). It is noteworthy that quinolones (Qs) have been observed to predominantly trigger immediate hypersensitivity reactions (IHRs). These reactions are categorized as either IgE-mediated or non-IgE-mediated, attributable to the off-target occupation of the recently described receptor, Mas-related G-protein coupled receptor member X2 (MRGPRX2), on effector cells.
View Article and Find Full Text PDFJ Dtsch Dermatol Ges
September 2025
Department of Dermatology, 921 Hospital of Joint Logistics Support Force, The Chinese People's Liberation Army, Changsha, China.
Background: Moderate to severe acne scars pose a therapeutic challenge and often require multimodal treatments. Ablative fractional laser (AFL) and fractional microneedling radiofrequency (FMR) are commonly used, but their alternating application has not been fully studied.
Patients And Methods: In this prospective, randomized, single-blind, split-face trial, 20 patients (Fitzpatrick III-IV) received four treatments at 4-week intervals: one facial side underwent alternating FMR (sessions 1, 3) and AFL (sessions 2, 4), while the contralateral side received AFL alone.
J Dermatolog Treat
December 2025
Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Background: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).
Objectives: This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients.
Methods: Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed.